[Market Movement Interpretation] AbCellera Biologics surged on September 17: ABCL635 data + antibody drug

1. On September 16, the company announced that it will present an oral report of Phase 2 clinical data on ABCL635, covering efficacy and safety data, at the 20th World Menopause Congress hosted by the International Menopause Society from September 30 to October 3.
2. On August 10, the company disclosed positive topline results from the ABCL635 Phase 2 trial; data shows that a single 600 mg dose reduced hot flash frequency by 83% and severity by 58% among 92 subjects, also improving sleep, with overall good safety.

(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)